Phase 4 N=10 Tolvaptan for Ascites in Cirrhotic Patients
Ascites · Cirrhosis
Primary: Number of Participants With Worsening Ascites (Increase in Number of Paracentesis Procedures to Remove 2 Liters of Ascites Fluid) — 0 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=29 Vasoconstrictors as Alternatives to Albumin After Large-Volume Paracentesis (LVP) in Cirrhosis
Ascites · Cirrhosis
Primary: Time to Recurrence of Ascites. — 10; 8 days — p=<0.05
Phase 3 N=33 Octreotide in Treating Patients With Cancer-Related Malignant Ascites
Metastatic Cancer · Unspecified Adult Solid Tumor, Protocol Specific
Primary: Median Time to Paracentesis — 28; 14 days — p=0.17
Phase 2 N=32 Study of the Trifunctional Antibody Catumaxomab to Treat Recurrent Symptomatic Malignant Ascites
Malignant Ascites
Primary: The Proportion of Patients Who Achieved at Least a 4-fold Increase of Puncture/Paracentesis-free Interval Following Catumaxomab Relative to Their Pre-treatment Interval…
Phase 2 N=6 Continuous Infusion Terlipressin for Patients With Cirrhosis and Refractory Ascites
Cirrhosis · Ascites Hepatic
Primary: Clinical Safety of Terlipressin Infusion in Cirrhotic Patients With Refractory Ascites — 6; 4; 3; 0 Participants
Phase 2 N=16 AVE0005 (VEGF Trap) in Patients With Recurrent Symptomatic Malignant Ascites
Ovarian Neoplasms
Primary: Percentage of Participants With a Repeat Paracentesis Response (RPR) — 62.5 percentage of participants
N/A N=136 Improving Performance of Paracentesis in Medical Residency Training
Ascites · Cirrhosis
Primary: Score Out of Total Possible 25 on a Likert Scale. — 21; 21; 20 units on a Likert scale (maximum is 25)
Phase 3 N=410 Effects of Long-Term Administration of Human Albumin in Participants With Decompensated Cirrhosis and Ascites
Decompensated Cirrhosis and Ascites
Primary: Time to Liver Transplantation or Death Through 1 Year After Randomization: Percentage of Participants With an Event — 33.5; 38.6 percentage of participants — p=0.17
Phase 3 N=55 Study of the Effect of Intravenous AVE0005 (VEGF Trap) in Advanced Ovarian Cancer Patients With Recurrent Symptomatic Malignant Ascites
Ovarian Neoplasms · Ascites
Primary: Time to Repeat Paracentesis (TRP) — 23.3; 55.1 days — p=0.0019
Phase 2 N=20 Alteplase for Percutaneous Treatment of Loculated Abdominopelvic Abscesses
Abdominal Abscess · Pelvic Abscess
Primary: Percentage of Patients Requiring Surgical Debridement for a Persistent Abscess Within 30 Days Following Initial Drainage — 3; 7 participants
Phase 2 N=104 A Dose-defining Study of OPC-41061 in Treatment of Hepatic Edema
Cirrhosis
Primary: Body Weight (Amount of Change) — -0.68; -2.31; -1.88; -1.67 Kg — p=0.3167
N/A N=649 Evaluation of the Strip PeriScreen for the Fast Diagnosis of the Spontaneous Infection of the Liquid of Ascites During the Cirrhosis
Cirrhosis · Liquid of Ascites · Infection
Primary: Sensitivity and Specificity — 91.7; 57.1; 12.0; 99.1 percentage
N/A N=25 Catheter Placement for Hepatic Hydrothorax
Pleural Effusion
Primary: Feasibility of Using Indwelling Tunneled Pleural Catheters for the Management of Hepatic Hydrothorax — 25 Participants
Phase 2 N=31 Study of Pemetrexed in Mesothelioma and Lung Cancer Patients With Fluid Around the Lungs or Abdomen
Non-small Cell Lung Cancer · Mesothelioma · Lung Neoplasms
Primary: Overview of Adverse Events — 28; 23; 12; 1 participants
Phase 3 N=162 A Trial to Investigate the Efficacy of OPC-41061 Administered at a Dose of 7.5 mg in Patients With Hepatic Edema
Cirrhosis
Primary: Body ｗeight — -1.95; -0.44 Kg — p=<0.0001
Phase 2 N=260 Local mEHT + TCM Versus Intraperitoneal Chemoinfusion in Treatment of Malignant Ascites: Phase II RCT
Peritoneal Neoplasms · Ascites · Yang Deficiency
Primary: Objective Response Rate (ORR) — 77.7; 63.8 percentage of participants — p=0.0140
N/A N=70 Velacur by Sonic Incytes for Portal Hypertension
Portal Hypertension · Chronic Advanced Liver Disease
Primary: Liver Stiffness Measurements for Participants With Compensated Advanced Chronic Liver Disease With and Without Esophageal Varices Upon Esophagogastroduodenoscopy (EGD)…
Phase 3 N=45 Furosemide and Albumin for Diuresis of Edema: A Pilot Randomized Controlled Trial
Edema · Hypoproteinemia
Primary: Ventilator-free Days — 4; 13 days
Phase 3 N=51 A Trial of OPC-41061 in Patients With Hepatic Edema - Investigation of the Safety of Treatment at 7.5 mg Beyond 7 Days and of the Effect of Dose Escalation to 15 mg
Cirrhosis
Primary: Body Weight — -0.76; -2.97; -0.05 Kg
N/A N=21 Lung Ultrasound in PD Patients
Peritoneal Dialysis · Hypervolemia · VEGF Overexpression
Primary: Association Between Number of Kerley B Lines by Ultrasound and Serum VEGF-C Level (pg/ml) by Enzyme-linked Immunosorbent Assay — 0.29; 0.25; 0.33 ng/ml — p=0.039
Phase 3 N=50 Terlipressin for HRS-AKI in Liver Transplant Candidates (INFUSE)
Hepatorenal Syndrome
Primary: Improvement of Renal Function (SCr) From Day 1 Thru End of Treatment, Repeated Measure Analysis. SCr Will be Collected Daily, From Day 1 Thru End of Treatment. Baseline…
Phase 4 N=33 Aquaresis Utility for Hyponatremic Acute Heart Failure Study
Heart Failure
Primary: Median Urine Output at 24 Hours Post Randomization — 2910; 3150 mL
Phase 3 N=40 A Study to Investigate Pharmacodynamics and Pharmacokinetics of OPC-41061 in Patients With Hepatic Edema
Cirrhosis
Primary: Body Weight — -1.14; -1.37 kg